ID   U266/ADM
AC   CVCL_GZ72
DR   cancercelllines; CVCL_GZ72
DR   Wikidata; Q54973632
RX   PubMed=26045737;
CC   Population: Caucasian.
CC   Characteristics: Produces IgE lambda (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0566 ! U266B1
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=26045737;
RA   Xu P., Jiang Y.-F., Wang J.-H.;
RT   "shRNA-mediated silencing of sorcin increases drug chemosensitivity in
RT   myeloma KM3/DDP and U266/ADM cell lines.";
RL   Int. J. Clin. Exp. Pathol. 8:2300-2310(2015).
//